Jun 14, 2007
By:
Brianne Harrison
Cambridge, MA (June 7)-Genzyme Corp. is growing, with a new biomanufacturing plant planned and other expansions nearing completion.
|
Jun 14, 2007
By:
Brianne Harrison
Brussels (May 30)-The European Federation of Pharmaceutical Industries and Associations (EFPIA) called for the pan-European and industry-wide adoption of 2-D barcode technology to combat the increase in counterfeit drugs in Europe.
|
Jun 7, 2007
By:
Brianne Harrison
Kvistgard, Denmark (June 4)-Bavarian Nordic received a $1.6-billion contract from the US Department of Health and Human Services to manufacture and deliver 20 million doses of its smallpox vaccine "Imvamune."
|
May 31, 2007
By:
Brianne Harrison
Rockville, MD (May 25)-The US Food and Drug Administration issued a statement announcing its intention to take action against companies that market unapproved timed-release drug products that contain the expectorant guaifenesin.
|
May 17, 2007
By:
Brianne Harrison
Rockville, MD (May)-The US Food and Drug Administration issued a draft guidance, "Labeling for Human Prescription Drugs-Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information."
|
May 10, 2007
By:
Brianne Harrison
Hamilton, OH (May 2)-Amylin Ohio LLC, a subsidiary of Amylin Pharmaceuticals, is expanding construction at its manufacturing facility in West Chester, Ohio. The expansion increases the company?s total investment to approximately $400 million.
|
May 10, 2007
By:
Brianne Harrison
Dublin, OH (May 3)-In preparation for California?s new pedigree legislation, Cardinal Health plans to integrate radio frequency identification (RFID) technology into the operations at its pharmaceutical distribution center in Sacramento by fall 2007.
|
May 3, 2007
By:
Brianne Harrison
Geneva, Switzerland (Apr. 27)-A meeting of the World Health Organization and the Committee for Medicinal Products for Human Use's approval of Novartis's new cell culture-derived influenza vaccine offered new hope that sufficient numbers of vaccines could be produced in case of a pandemic.
|
Apr 27, 2007
By:
Brianne Harrison
Interphex2007, New York, NY (Apr. 26)-As focus shifts away from "one-size-fits-all" medicines and begins centering on personalized medicines, many companies begin to wonder how they can manufacture such drugs economically. Mark Hirschel, chief scientific officer of BioVest International, addressed that issue in his presentation, "A Bioreactor System Designed for Production of Personalized Therapeutics," at Interphex on Thursday.
|
|
